Role of detection method in predicting breast cancer survival: Analysis of randomized screening trials

Journal of the National Cancer Institute

Volumn 97, Issue 16, 2005, Pages 1195-1203

  Shen, Yu ^a   Yang, Ying ^a   Inoue, Lurdes Y T ^b   Munsell, Mark F ^a   Miller, Anthony B ^c   Berry, Donald A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANADA; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC PROCEDURE; FEMALE; HAZARD ASSESSMENT; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; UNITED STATES; BREAST TUMOR; DISEASE FREE SURVIVAL; LYMPH NODE METASTASIS; MASS SCREENING; META ANALYSIS; METHODOLOGY; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RADIOGRAPHY; RISK; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; SURVIVAL RATE;

BREAST NEOPLASMS; CANADA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MAMMOGRAPHY; MASS SCREENING; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; UNITED STATES;

EID: 23844500059     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji239     Document Type: Article

References (38)

1. Shapiro S, Goldberg JD, Hutchinson GB. Lead time in breast cancer detection and implications for periodicity of screening. Am J Epidemiol 1974;100:357-66.
2. Chu KC, Smart CR, Tarone RE. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trials. J Natl Cancer Inst 1988;80:1125-32.
3. Connor RJ, Chu KC, Smart CR. Stage-shift cancer screening model. J Clin Epidemiol 1989;42:1083-95.
4. Albert A, Gertman PM, Louis TA, Liu SI. Screening for the early detection of cancer - II. The impact of screening on the natural history of the disease. Math Biosci 1978;40:61-109.
5. Morrison AS. Screening in chronic disease. New York (NY): Oxford University Press; 1985.
6. Kramer BS, Gohagan JK, Prorok PC. Cancer screening: Theory and practice. New York (NY): Marcel Dekker; 1999.
7. Otto SJ, Fracheboud J, Looman CW, Broeders MJ, Boer R, Hendriks JH, et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: A systematic review. Lancet 2003;361:1411-7.
8. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003;361:1405-10.
9. Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004;292:1064-73.
10. Heuser LS, Spratt JS, Kuhns JG, Chang AF, Polk HC Jr, Buchanan JB. The association of pathologic and mammographic characteristics of primary human breast cancers with 'slow' and 'fast' growth rates and with axillary lymph node metastases. Cancer 1984;53:96-8.
11. Hakama M, Holli K, Isola J, Kallioniemi OP, Karkkainen A, Visakorpi T, et al. Aggressiveness of screen-detected breast cancer. Lancet 1995;345: 221-4.
12. Petersen GM, Parmigiani G, Thomas D. Missense mutations in disease genes: A Bayesian approach to evaluate causality. Am J Hum Genet 1998;62:1516-24.
13. Shapiro S. Periodic screening for breast cancer: The HIP randomized controlled trial. J Natl Cancer Inst Monogr 1997;22:27-30.
14. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study: Update on breast cancer mortality. J Natl Cancer Inst Monogr 1997;22:37-41.
15. Miller AB, To T, Baines CJ, Wall C. Canadian national breast screening study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 2000;92:1490-9.
16. Miller AB, To T, Baines CJ, Wall C. Canadian national breast screening study-1: Breast cancer mortality after 11 to 16 year of follow-up. A randomized screening trial of mammography in women aged 40-49 years. Ann Intern Med 2002;137:305-12.
17. Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE. Long-term effects of mammography screening: Updated overview of the Swedish randomized trails. Lancet 2002;359:909-19.
18. Alexander FE, Anderson TJ, Brown HK, Forrest AP, Hepburn W, Kirkpatrick AE, et al. The Edinburgh randomised trial of breast cancer screening: results after 10 years of follow-up. Br J Cancer 1994;70:542-8.
19. Shapiro S, Strax P, Venet L. Evaluation of periodic breast cancer screening with mammography. JAMA 1966;195:731-8.
20. Miller AB, Baines CJ, To T, Wall C. Canadian national breast screening study: 1. Breast cancer detection and death rates among women aged 40-49 years. Can Med Assoc J 1992;147:1459-76.
21. Miller AB, Baines CJ, To T, Wall C. Canadian national breast screening study: 2. Breast cancer detection and death rates among women aged 50-59 years. Can Med Assoc J 1992;147:1477-88.
22. Shapiro S, Venet W, Strax P, Venet L. Periodic screening for breast cancer. The health insurance plan project and its sequelae. Baltimore (MD): Johns Hopkin University Press; 1988.
23. Fleming ID, Cooper IS, Henson DC (editors). American Joint Committee on Cancer Staging Manual, 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 1997. p. 171-80.
24. Therneau TM, Grambsch PM. Modeling survival data: Extending the Cox model. New York (NY): Springer; 2000.
25. Connor RJ, Eng D, Prorok PC. Issues in the mortality analysis of randomized controlled trials of cancer screening. Control Clin Trials 1994;15:81-99.
26. Baines CJ, Miller AB, Bassett AA. Physical examination. Its role as a single screening modality in the Canadian national breast screening study. Cancer 1989;63:1816-22.
27. Baines CJ. Screening for breast cancer: How useful are clinical breast examinations? J Natl Cancer Inst 2000;92:958-9.
28. Bobo JK, Lee NC, Thames SF. Findings from 752 081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst 2000;92:971-6.
29. Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: Mammograms and physical examinations. J Clin Oncol 2001;19:3490-9.
30. Tabar L, Chen HH, Fagerberg G, Duffy SW, Smith TC. Recent results from the Swedish two-county trial: The effects of age, histologic type and mode of detection on the efficacy of breast cancer screening. J Natl Cancer Inst Monogr 1997;22:43-7.
31. Holland R, Mravunac M, Hendriks JH, Bekker BV. So-called interval cancers of the breast. Pathologic and radiologic analysis of sixty-four cases. Cancer 1982;49:2527-33.
32. Brekelmans CT, van Gorp JM, Peeters PH, Collette HJ. Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 1996;78:1220-8.
33. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, et al. Breast tumor characteristics as predictors of mammographic detection: Comparison of interval- and screen-detected cancers. J Natl Cancer Inst 1999;91:2020-8.
34. Gilliland ED, Joste N, Stauber PM, Hunt WC, Rosenberg R, Redlich G, et al. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 2000;92:743-9.
35. Duffy SW, Hill C, Esteve J. Quantitative methods for the evaluation of cancer screening. London (UK): Arnold; 2001.
36. Lacroix M, Toillon RA, Leclercq G. Stable portrait of breast tumors during progression: Data from biology, pathology and genetics. Endocr Relat Cancer 2004; 11:497-522.
37. Bernards R, Weinberg RA. A progression puzzle. Nature 2002;418:823.
38. Berry DA, Inoue LY, Shen Y, Venier J, Cohen D, Bondy M, et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: A Bayesian approach. J Natl Cancer Inst Monogr. In press, 2005.